Skip to main content
Top
Published in: Breast Cancer 5/2014

01-09-2014 | Original Article

GeneSearch™ BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes

Authors: Yong-sheng Wang, Yan-hui Liu, Tao Ou-yang, Xin-hua Yang, Jiong Wu, Feng-xi Su, Xiao Sun, Wei-xia Zhong, Ning Liao, Wen-tao Yang

Published in: Breast Cancer | Issue 5/2014

Login to get access

Abstract

Background

Breast cancer sentinel lymph node (SLN) biopsy has become a common procedure. The GeneSearch™ Breast Lymph Node Assay is a real-time reverse-transcriptase polymerase chain reaction assay for detecting nodal metastases larger than 0.2 mm. The trial is a prospective multi-center clinical trial conducted to validate the assay in China.

Methods

Four hundred and seventy-nine consecutive prospective patients were enrolled from six centers. SLNs were sectioned along the short axis into multiple blocks. Odd blocks were tested by the assay intra-operatively, and even blocks were assessed by post-operative histology. Six 4- to 6-μm-thick sections were taken every 150 μm per block. In addition, intra-operative histological assessments were performed on the even blocks of 214 patients by frozen section (FS) and all blocks of 156 patients by touch imprint cytology (TIC).

Results

A total of 1046 SLNs were excised. Overall performance of the assay compared to post-operative histology was accuracy of 91.4 %, sensitivity of 87.5 %, and specificity of 92.9 %. There were no significant differences in assay performance of each center. After a learning curve of about 10 cases, the assay could be performed in a median time of about 35 min. The sensitivity of the assay was similar to the FS (84.9 %, P = 0.885) and was significantly higher than the TIC (70.0 %, P = 0.007) while the specificity of all were comparable.

Conclusion

The GeneSearch™ Breast Lymph Node Assay is an accurate and rapid intra-operative assay for breast SLNs and it can replace FS and TIC for application.
Literature
1.
go back to reference Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91:368–73.PubMedCrossRef Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91:368–73.PubMedCrossRef
2.
go back to reference Posther KE, Wilke LG, Giuliano AE. Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol. 2004;31:426–36.PubMedCrossRef Posther KE, Wilke LG, Giuliano AE. Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol. 2004;31:426–36.PubMedCrossRef
3.
go back to reference Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef
4.
go back to reference Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, et al. Special report: consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009;9:504–20.CrossRef Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, et al. Special report: consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009;9:504–20.CrossRef
5.
go back to reference Langer I, Guller U, Berclaz G, Koechli OR, Moch H, Schaer G, et al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat. 2009;113:129–36.PubMedCrossRef Langer I, Guller U, Berclaz G, Koechli OR, Moch H, Schaer G, et al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat. 2009;113:129–36.PubMedCrossRef
6.
go back to reference Tew K, Irwig L, Matthews A, Crowe P, Macaskill P. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg. 2005;92:1068–80.PubMedCrossRef Tew K, Irwig L, Matthews A, Crowe P, Macaskill P. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg. 2005;92:1068–80.PubMedCrossRef
7.
go back to reference Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.CrossRef Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.CrossRef
8.
go back to reference Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008;26:3338–45.PubMedCrossRef Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008;26:3338–45.PubMedCrossRef
9.
go back to reference Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.PubMedCentralPubMedCrossRef Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.PubMedCentralPubMedCrossRef
10.
go back to reference de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653–63.PubMedCrossRef de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653–63.PubMedCrossRef
11.
go back to reference Tjan-Heijnen VC, Pepels MJ, de Boer M, Borm GF, van Dijck JA, van Deurzen CH, et al. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+] in the sentinel lymph node (SN): results from the MIRROR study. 2009 ASCO. Abstract CRA596. Tjan-Heijnen VC, Pepels MJ, de Boer M, Borm GF, van Dijck JA, van Deurzen CH, et al. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+] in the sentinel lymph node (SN): results from the MIRROR study. 2009 ASCO. Abstract CRA596.
12.
go back to reference Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, et al. A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. 2011 ASCO. Abstract CRA504. Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, et al. A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. 2011 ASCO. Abstract CRA504.
13.
go back to reference Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–75.PubMedCrossRef Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–75.PubMedCrossRef
14.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedCentralPubMedCrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedCentralPubMedCrossRef
15.
go back to reference van de Vrande S, Meijer J, Rijnders A, Klinkenbijl JH. The value of intraoperative frozen section examination of sentinel lymph nodes in breast cancer. Eur J Surg Oncol. 2009;35:276–80.PubMedCrossRef van de Vrande S, Meijer J, Rijnders A, Klinkenbijl JH. The value of intraoperative frozen section examination of sentinel lymph nodes in breast cancer. Eur J Surg Oncol. 2009;35:276–80.PubMedCrossRef
16.
go back to reference Chicken DW, Kocjan G, Falzon M, Lee AC, Douek M, Sainsbury R, Keshtgar MR, et al. Intraoperative touch imprint cytology for the diagnosis of sentinel lymph node metastases in breast cancer. Br J Surg. 2006;93:573–6. Chicken DW, Kocjan G, Falzon M, Lee AC, Douek M, Sainsbury R, Keshtgar MR, et al. Intraoperative touch imprint cytology for the diagnosis of sentinel lymph node metastases in breast cancer. Br J Surg. 2006;93:573–6.
17.
go back to reference Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem. 2004;37:249–57.PubMedCrossRef Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem. 2004;37:249–57.PubMedCrossRef
18.
go back to reference Ishida M, Kitamura K, Kinoshita J, Sasaki M, Kuwahara H, Sugimachi K. Detection of micrometastasis in the sentinel lymph nodes in breast cancer. Surgery. 2002;131:211–6.CrossRef Ishida M, Kitamura K, Kinoshita J, Sasaki M, Kuwahara H, Sugimachi K. Detection of micrometastasis in the sentinel lymph nodes in breast cancer. Surgery. 2002;131:211–6.CrossRef
19.
go back to reference Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg. 2007;194:426–32.PubMedCrossRef Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg. 2007;194:426–32.PubMedCrossRef
20.
go back to reference Viale G, Dell’Orto P, Biasi MO, Stufano V, De Brito Lima LN, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg. 2008;247:136–42.PubMedCrossRef Viale G, Dell’Orto P, Biasi MO, Stufano V, De Brito Lima LN, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg. 2008;247:136–42.PubMedCrossRef
21.
go back to reference Martin Martinez MD, Veys I, Majjaj S, Lespagnard L, Schobbens JC, Rouas G, et al. Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes. Eur J Surg Oncol. 2009;35:387–92.PubMedCrossRef Martin Martinez MD, Veys I, Majjaj S, Lespagnard L, Schobbens JC, Rouas G, et al. Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes. Eur J Surg Oncol. 2009;35:387–92.PubMedCrossRef
22.
go back to reference Mansel RE, Goyal A, Douglas-Jones A, Woods V, Goyal S, Monypenny I, et al. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch™ BLN Assay in the operating room: results of the Cardiff study. Breast Cancer Res Treat. 2009;115:595–600.PubMedCrossRef Mansel RE, Goyal A, Douglas-Jones A, Woods V, Goyal S, Monypenny I, et al. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch™ BLN Assay in the operating room: results of the Cardiff study. Breast Cancer Res Treat. 2009;115:595–600.PubMedCrossRef
23.
go back to reference Veys I, Majjaj S, Salgado R, Noterman D, Schobbens JC, Manouach F, et al. Evaluation of the histological size of the sentinel lymph node metastases using RT-PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer. Breast Cancer Res Treat. 2010;124:599–605.PubMedCrossRef Veys I, Majjaj S, Salgado R, Noterman D, Schobbens JC, Manouach F, et al. Evaluation of the histological size of the sentinel lymph node metastases using RT-PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer. Breast Cancer Res Treat. 2010;124:599–605.PubMedCrossRef
24.
go back to reference Funasako Y, Uenosono Y, Hirata M, Arigami T, Yanagita S, Arima H, et al. Utility of the GeneSearch breast lymph node assay for the rapid evaluation of sentinel lymph nodes in breast cancer. Cancer. 2010;116:4450–5.PubMedCrossRef Funasako Y, Uenosono Y, Hirata M, Arigami T, Yanagita S, Arima H, et al. Utility of the GeneSearch breast lymph node assay for the rapid evaluation of sentinel lymph nodes in breast cancer. Cancer. 2010;116:4450–5.PubMedCrossRef
25.
go back to reference Sun X, Liu JJ, Wang YS, Song XR, Zhong WX, Zhou CC, et al. Using intra-operative GeneSearch™ Breast Lymph Node Assay to detect breast cancer metastases in sentinel lymph nodes: results from a single institute in China. Chin Med J (Engl). 2011;124:973–7. Sun X, Liu JJ, Wang YS, Song XR, Zhong WX, Zhou CC, et al. Using intra-operative GeneSearch™ Breast Lymph Node Assay to detect breast cancer metastases in sentinel lymph nodes: results from a single institute in China. Chin Med J (Engl). 2011;124:973–7.
26.
go back to reference Chen JJ, Yang BL, Chen JY, Zhang JX, Li DL, Xu WP, et al. A prospective comparison of molecular assay and touch imprint cytology for intraoperative evaluation of sentinel lymph nodes. Chin Med J (Engl). 2011;124:491–7. Chen JJ, Yang BL, Chen JY, Zhang JX, Li DL, Xu WP, et al. A prospective comparison of molecular assay and touch imprint cytology for intraoperative evaluation of sentinel lymph nodes. Chin Med J (Engl). 2011;124:491–7.
27.
go back to reference Liu YH, Xu FP, Liao N, Li L, Zhang GC, Zhuang HG, et al. Efficacy of intraoperative GeneSearch Breast Lymph Node (BLN) Assay for breast cancer metastasis detection in sentinel lymph node in Chinese patients. Cancer Sci. 2010;101:1920–4.PubMedCrossRef Liu YH, Xu FP, Liao N, Li L, Zhang GC, Zhuang HG, et al. Efficacy of intraoperative GeneSearch Breast Lymph Node (BLN) Assay for breast cancer metastasis detection in sentinel lymph node in Chinese patients. Cancer Sci. 2010;101:1920–4.PubMedCrossRef
Metadata
Title
GeneSearch™ BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes
Authors
Yong-sheng Wang
Yan-hui Liu
Tao Ou-yang
Xin-hua Yang
Jiong Wu
Feng-xi Su
Xiao Sun
Wei-xia Zhong
Ning Liao
Wen-tao Yang
Publication date
01-09-2014
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0437-z

Other articles of this Issue 5/2014

Breast Cancer 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine